myelodysplastic syndromes (MDS) | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

2019 Patient & Family Conference (Rockville, Maryland)

Thank you for attending the 2019 Patient & Family Conference in Rockville, Maryland. 

Event Date: 
Sat, 05/18/2019 - 7:30am
Conference Event Type: 

Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis

Author(s): 
Stahl M, Bewersdorf JP, Giri S, Wang R, Zeidan AM
Primary Author: 
Stahl M
Journal Title: 
Haemotologica
Original Publication Date: 
Apr 2019

Immunosuppressive therapy is one therapy option for treatment of patients with lower-risk

Bone Marrow Diseases: 

Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes

Author(s): 
Hsu J, Reilly A, Hayes BJ, Clough CA, Konnick EQ, Torok-Storb B, Gulsuner S, Wu D, Becker PS, Keel SB, Abkowitz JL, Doulatov S
Primary Author: 
Hsu J
Journal Title: 
Blood
Original Publication Date: 
Apr 2019

Myeloid neoplasms, including

Bone Marrow Diseases: 

MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge

Author(s): 
Sanders DS, Fennell T, Chisti MM
Primary Author: 
Sanders DS
Journal Title: 
BMJ Case Reports
Original Publication Date: 
Apr 2019

A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat

Bone Marrow Diseases: 

Clonal Hematopoiesis and therapy related MDS/AML

Author(s): 
Desai P, Roboz GJ
Primary Author: 
Desai P
Journal Title: 
Best Practice & Research. Clinical Heamatology
Original Publication Date: 
Mar 2019

Clonal Hematopoiesis is defined as the presence of mutations in peripheral blood in the absence of myeloid malignancies and is thought to occur as a normal part of ageing due to the fitness advantage conferred by these mutations in an ageing hematopoietic compartment.

Bone Marrow Diseases: 

A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)

Author(s): 
Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE.
Primary Author: 
Sallman DA
Journal Title: 
Leukemia Research
Original Publication Date: 
Mar 2019

Hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) patients have poor outcomes and urgent need for novel therapies. Hedgehog pathway signaling upregulation plays a central role in myeloid neoplasm pathogenesis and leukemia stem cell survival. We evaluated the efficacy and safety of the smoothened inhibitor glasdegib in HMA-failure MDS (n = 35, median age 73 years). According to the

Bone Marrow Diseases: 

Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications.

Author(s): 
Wong SA, Dalal BI, Leitch HA
Primary Author: 
Wong SA
Journal Title: 
Curr Oncol
Original Publication Date: 
Oct 2018
Background: